by Mary
Shomon
Mary Shomon: Can you introduce yourself, tell us a bit about your background, and how you
came to be interested in thyroid disease, and how people can find out more about you if they're
interested?
John DOMmisse, MD, FRCP(C): I'll start by making 1 or 2 disclaimers. I am not an endocrinologist,
or even an internist; my MD is from the U of CapeTown and my (Canadian) board-certification was in
psychiatry (accepted in Arizona and some other states). In 1987, I ordered a TSH on myself and it was 6.0
mIU, 1.0-2.0 points above the 'normal range'. I saw an endocrinologist, who repeated the tests and then
started treating me with Synthroid (T4). He was an open-minded person who also happened to be
fascinated by the stories of psychiatrists and others 'bringing people back to life' with T3 (Cytomel). So,
when I never felt that the T4 'did the whole job', I started experimenting with adding Cytomel to - or
substituting Armour Thyroid for - the Synthroid. I have never looked back. After all the studying I did on the
subject, I started treating patients for hypothyroidism as well, and now regard myself as an expert on the
subject. My correction of nutritional and metabolic deficiencies in the blood has led me to treat also
isolated aspects of other specialties; it would not be feasible to specialize and take specialty training in
each one of these diverse areas of medicine, so I just call myself a nutritional-metabolic physician (for
which there is no board-certification) and treat the conditions I am able to. Psychiatry is now only my 3rd
specialty-area, after nutritional and metabolic medicine. My publications are listed - and some printed out -
on my website, where there are about 160 pages of free info, plus my semi-annual Natural Medicine
NewsLetter, containing case-reports from my practice, are for sale at $3-5.00 each, depending on the
number ordered: www.JohnDommisseMD.com.
MS: What are your thoughts about the use of the TSH test and its "normal range" as a
primary means of diagnosis of hypothyroidism?
JD: Not much. 2 reasons: (1) The TSH is an indirect measure of the height of
thyroid hormone function and is influenced by many factors in addition to the height of the
free-T4 and free-T3 serum levels. Endocrinologists are confusing the great sensitivity of
the test (for measuring the height of the thyroid stimulating hormone serum level) with the
idea that it is therefore the most accurate and appropriate measure of T4 and T3 thyroid
hormone function, which it is not - the free-T4 and free-T3 serum levels are the best
arbiters of that! They are still 'stuck' in the time when the Total-T4 and Total-T3 (and other
even-less-accurate measures) were the only measures available. They have not adapted
to the paradigm-shift in accuracy of the free-levels. Besides, an elevated TSH can only
suggest primary hypothyroidism (in which the defect is in the thyroid gland itself), not
secondary, tertiary or nonthyroidal-illness hypothyroidism (in which the
defect is in the pituitary, hypothalamus, and peripheral enzymatic
conversion of T4-to-T3 with 5'deiodinase, respectively, and TSH is not
elevated in these types of hypothyroidism, may even be below its 'normal
range'). If the TSH has any usefulness at all, it only has it in a trio
of tests including the FT4 and FT3 as well. There are many
circumstances in which one can dispense with the TSH test, but never, in
my opinion, with the FT4 and FT3 levels.
(2) The so-called 'normal range' is way too high. Even in conventional circles it has
become acceptable to make a diagnosis of grade-3 hypothyroidism (the mildest grade)
when the TSH level is "in the upper half of its 'normal
range'" (above 2.0, rather than 4.0 or 5.0 mIU), although very few conventional
physicians will do this, or treat this 'mild, sub-subclinical' degree of hypothyroidism. But
isn't that strange? Doesn't that immediately render the TSH normal range cut in half,
to a new normal range of 0.4-2.0? For several years I adhered to the grade-3 primary
hypothyroidism range, with 2.0 as my cut-off point. But, eventually, I ran into too many
patients who had classic hypothyroid symptoms, which cleared completely on
appropriate thyroid treatment, and whose TSH
was below 2.0 (but above 1.5) and with FT4 and FT3 levels in the low ends of their
'normal ranges'. So I lowered my range to 0.2-1.5. For several months I was happy to
be helping more people (those whose TSH fell between
1.5 and 2.0). Finally, I found some patients with several symptoms and signs of
hypothyroidism whose TSH was between 1.0-1.5; so I lowered my range, for the last
time, to 0.1-1.0; I now treat primary hypothyroidism
with a TSH of >1.0 (if the FT4 and FT3 are low-normal, not above the middle of their
'normal ranges'). Some physicians are still waiting for the TSH to go above 6.0 or even
10.0 mIU before they'll agree that the patient's hypothyroidism needs
treatment!
MS: How do you typically diagnose hypothyroidism in your
patients?
JD: I diagnose primary hypothyroidism in the way indicated in my first answer,
above. Pituitary, hypothalamic and
nonthyroidal-illness hypothyroidism require a FT3 level, at least, if not the FT4 as well, to
be below its 'normal range'. That raises the question of what the normal range for FT3
really is. When I first started treating hypothyroidism, in 1988/9, the national chain-lab that
I used most used a normal range for free-T3 of 280-540 (or 2.8-5.4, depending on the size
of the units). It later lowered that range to comply with the ranges used at most other large
chain-labs: 2.3-4.2 (or 230-420). I have often wondered whether that lab should have stuck
to its guns and stayed with the higher range, and I have occasionally returned to that higher
range in treating certain patients who particularly seemed to cry out (not literally or
emotionally but in their symptoms and signs) for that higher range.
MS: What is your advice to patients who have physicians who insist that having
a normal range TSH value means that hypothyroidism cannot be diagnosed?
JD: This claim is only reasonable for primary hypothyroidism, not for any other
type. Even with regard to primary hypothyroidism, I would disagree, and I would repeat
what I have just said, above, in answer to your previous questions.
MS: What about the TRH Stimulation Test?
JD: Thyroid stimulating hormone is also known as thyrotropin. It is secreted
from the pituitary gland, to stimulate the thyroid gland to secrete enough thyroid
hormones to carry out all the metabolic functions required of these crucial hormones,
T4 and T3. The pituitary, in turn, is dependent on a certain amount of stimulation by
the hypothalamus, a small part of the lower-anterior brain. The hypothalamus does this
by secreting the thyrotropin-releasing hormone (TRH). Researchers like Evered,
Ormston, Wentzel, Gold, Pottash and Extein discovered that there are a certain
number of patients with normal TSH levels whose TSH level will jump up by more than
20 points 30 minutes after an injection of a certain amount of TRH.
These were the first patients to be called grade-3-primary-hypothyroid
(grade-1 being those whose FT4 and FT3 levels are below their normal
ranges despite the best efforts of the TSH; and grade-2 being those whose
TSH is elevated above its normal range but this TSH elevation is managing
to keep the FT4 and FT3 levels in the low parts of their normal ranges).
With the development of
increasingly-sensitive TSH tests, it was
realized that a basal sensitive-TSH is
sufficient to diagnose grade-3 if one
reads all those who are in the upper half
of the TSH's 'normal range' as being
grade-3. When I first read Gold, Pottash
and Extein's papers about the TRH
stimulation test uncovering mild or
'subclinical' degrees of hypothyroidism,
whose treatment then rescued them from
refractory depression and other conditions
resulting from this low-level
hypothyroidism, I called them up and asked
whether the patients whose TSH shot up >20
points after the TRH injection were not
also the ones whose TSH was hi-normal in
the first place, and Dr Extein admitted
that this was the
case. At that time, the TRH stimulation test cost $600.00, so I bypassed
that expense for my patients and started to diagnose all cases with TSH >
2.0 (and FT4 and FT3 low-normal) as grade-3 hypothyroidism, and started
treating them. All of them improved dramatically.
So when physicians
talk about 'subclinical' hypothyroidism (meaning 'no symptoms'), I am
shocked because I realize they have simply not elicited the history or
signs of classic hypothyroidism that seem, to me, to invariably accompany
grade-3 hypothyroidism. As I've said, I now treat people whose TSH is
> 1.0 (with FT4 and FT3 lo-normal) and, so far, have always obtained an
excellent improvement in the patient's symptoms, cholesterol level, or
whatever they have presented with. For some reason that I don't
understand, there is more fear of treating these minor degrees of
hypothyroidism than of treating the more-severe degrees, the implication
being that, since they are only slightly low, they are that much closer to
being overtreated. The reason I don't understand this is because one
obviously uses smaller doses in the milder cases than in the more-severe
ones, and one monitors their FT4 and FT3 levels at the point when they
reach their maximum effect for each dosage-level anyway, so I fail to see
what the danger is. I don't believe I have ever seen a patient's FT4
and/or Ft3 level go too high after the initial dose of thyroid hormone(s);
one starts with a lowish dose, re-tests, increases the dose, etc., until
both levels are optimized, whether the patient started out as a severe
case or a mild case.
MS: What are your thoughts about the need for T3 in addition to
T4 as a treatment for hypothyroidism?
JD: In my opinion, it is essential in most cases, in order to
obtain the optimal response to treatment. There is a minority
of hypothyroid cases that is able to convert T4 sufficiently to
T3 in the peripheral tissues to produce an optimal free-T3
level, as well as an optimal free-T4 level, without prescribing
any T3-containing preparation. I don't have any fixed
combination of T4 and T3 that I use. The most important thing
to do when prescribing any T3-containing preparation is to
write it as a twice-daily, after brkfst and supper,
prescription. This is because, unlike the T4-hormone, T3 is
rather short-acting, with a half-life of 8-12 hours (meaning
that half of it is already metabolized away in that time).
This is the
fact that has scared many conventional physicians off from prescribing any
T3-containing preparations. But this fear and objection is entirely
taken-care-of by this prescribing regimen. So easy! This is not to imply
that there are not many dangers involved in prescribing any thyroid
preparation - and, even with this regimen, T3 is still more volatile than
T4. e.g., If a patient misses a daily dose of T4, it will not
significantly affect the blood-level drawn on that day; but, if a patient
misses any dose of a T3-containing preparation in the 48 hrs leading up to
the blood-draw, esp. the morning dose on that day, the serum free-T3 level
is going to look lower than it has actually been running when the patient
took every dose regularly. And temporary surges of free-T3 are all that
are needed to cause cardiac arrhythmias and other significant problems in
susceptible individuals. So perhaps it is not for the faint-of-heart,
esp. if the prescriber endeavors to maintain the free-T3 level close to
the maximum tolerable level for each particular patient. Frail, elderly,
cardiac-arrhythmic and seriously-ill persons' free-T3 levels should not be
run at hi-normal levels but only in the mid-range. But, with careful
dosing, it is completely 'do-able' and well worth the extra attention
needed.
If I start out with a T4/T3 combination like Armour
Thyroid (because the free-T3 level in that patient is
significantly lower, relatively-speaking, than the
free-T4 level), this becomes the only treatment, again,
in a minority of cases. In most cases, the free-T3
level will be elevated higher than the free-T4 level by
Armour Thyroid. In that case, I add small to moderate
daily doses of T4 - whatever is required to optimize
both the free-T3 and free-T4 levels. If I start out
with T4-only (Levoxyl or Levothroid*), I will add
T3-only (Cytomel) twice-daily if the FT4 level is
totally optimized but T3 is lagging; and I will add
Armour Thyroid twice-daily if the FT4 level is still
suboptimal and the FT3 level is even
lower. There is also a synthetic T4/T3 combo, called Thyrolar, but it is
much more expensive and w/o any real advantages except in cases of
sensitivity to the pork thyroid gland in Armour (very rare).
Sensitivities to cornstarch and other fillers are much more common; in
such cases, I do compounded prescriptions, to be filled by a compounding
pharmacist who puts all the ingredients together himself, from scratch.
There are several of these kinds of pharmacies dotted around the country,
and they have gotten quite heavily into mailing supplies to patients in
remote locales.
*I avoid Synthroid unless the patient's
insurance mandates this brand for payment
purposes, because the then manufacturers
of Synthroid, the Boots Co., did some very
unethical stuff in relation to the
non-publication of an article in the early
90's that proved that Levoxyl ('Levoxine'
at the time) and Levothroid were equal to,
or very slightly better than, Synthroid.
MS: Many patients have told me that they've brought the New
England Journal study and Dr. Ridha Arem's book to their
doctors, but the doctors have said that the study wasn't
enough to prove anything, dismissing the results, and
decrying the study as flawed or inadequate. Why do you think
this is happening, and there's such resistance to the use of
T3?
JD: I've explained some of the resistance to T3 above.
The rest of the resistance has to do with the conservatism
that many doctors are influenced or coerced to adopt
because of the huge survival- and career-jeopardizing
pressures that physicians who 'step out of line' are
subjected to, by medical boards, plaintiff lawyers, other
physicians, medical schools, etc., etc.. As you probably
know, the very issue of the New England J of Med (that
published the Bunevicius et al article about T4+T3 being
better than T4-only for many hypothyroid patients)
contained a sort of disclaimer-editorial, written by Prof.
Anthony Toft of Edinburgh, in which the significance of the
article was placed under the qualification that 'further
studies are required to verify these findings'. Prof. Toft said his
impression is that most hypothyroid patients treated with T4-only are
quite satisfied with their treatment!
Let me also say this about the Bunevicius
et al paper in the NEJM on Feb. 11. These
4 workers merely substituted a fixed
amount (12.5 mcg) of T3 for 50 mcg of the
T4 that 33 patients were taking for their
hypothyroidism; they did not, by any
means, optimize the FT4 and Ft3 serum
levels. And STILL, many of the patients
improved when the T3 was substituted. My
contention is that they would have
improved even much more if their FT4 and
FT3 levels had both been optimized.
MS: Some doctors claim that T3 is dangerous to use because
it increases the risks of osteporosis or heart palpitations,
among other claims. Are there any proven dangers in use of
T3?
JD: There definitely are dangers inherent in prescribing T3
if one doesn't know how to do it. The reverse-side of that
is that, if one knows how to prescribe it, the dangers can
be minimized and kept to a level that is no higher than the
dangers inherent in prescribing T4-only. The dangers are
increased if one has the approach that both thyroid hormone
levels should be kept optimal (for that individual) at all
times. There is not much danger of over-treatment if all
you are trying to do is "put the TSH and, perhaps the T4
level, in its normal range" because you are sailing 'far
from the edge' in that case. But your patient is going to
suffer the overall disadvantages of continuing to run a
low-normal, sub-optimal level
of both hormones. In my view, these disadvantages (which I'm sure most
people reading this interview are very familiar with) are far, far greater
than the potential dangers of over-treatment, if one knows how to
prescribe T3 and monitors the FT4 and FT3 levels regularly.
The commonest cause of palpitations, in my
experience, is intracellular hypokalemia
(a low potassium level in the red blood
cells). This test is hardly ever done;
the serum level is the one usually done
but it won't pick up most cases of low
potassium where it counts, which is INSIDE
the cells, not outside them, in the serum.
The red cell level reflects the level
inside heart cells, muscle cells, etc..
It is tragic how many sportspeople are
forced out of competitions because their
physicians didn't measure the
INTRACELLULAR potassium level and pick up
their deficiencies that cause muscle
cramps, heart problems, etc.. But a high
T3 level can add to the risk of cardiac
arrhythmias, so patients who have
this tendency should have their free-T3 levels kept in the mid-range and
not near the top of the normal range, which is where I like it in young,
middle-aged otherwise-healthy people.
The danger of osteoporosis is
way-overblown and is the reason why many
hypothyroid cases are not diagnosed as
such (because then the physician has to
subject himself to this supposed high risk
of being sued for having caused or
aggravated the osteoporosis). It is
strange that the free-T3 level should be
picked on in this fearful strategy because
hardly any of the studies that have been
done on thyroid treatment causing
osteoporosis have even measured the
free-T3 levels of those patients! In
fact, the free-T3 level is seldom
obtained, period. And this is the level
that does 90% of the thyroid function!
The main reason why I know the fear of
osteoporosis is overblown is that all my
patients who are both
hypothyroid and osteoporotic see their bone mineral density x-ray scans
not only not deteriorate every year, but actually improve - by as much as
30 percentage-points in one year! If osteoporosis can be caused or
aggravated by aggressive, hi-normal thyroid treatment, then surely my
patients would be prime suspects to show this phenomenon. But they don't.
Admittedly, I do also correct many mineral, vitamin, amino-acid and other
hormone deficiencies, many of which cause or aggravate osteoporosis, but
at least I have proven that, in a fairly-unique practice that does attend
to such deficiencies, there is not only no danger of osteoporosis, there
is reversal of osteoporosis. And this is without the use of Fosamax,
calcitonin or any other drugs that are usually prescribed for
osteoporosis.
MS: What do you think of Prof. Ridha Arem's new book, 'The
Thyroid Solution', published in June by Ballantine Books?
JD: I read it in a few days, fascinated, because here, virtually for the first
time, was a conventional
endocrinologist who (1) actually listened to his patients,
including the female ones, and responded to their needs
rather than, in the usual cold academic way, brushing them
off with "The problem is not in your thyroid gland, it is
normal. Next case, please.";
(2) admitted that the standard approach
is not the answer in many cases, that
some patients 'with normal blood values'
do seem to be hypothyroid and to respond
to treatment with thyroid hormone (T4);
(3) added small doses of T3 2-3 times
per day in some cases who did not
respond favorably to T4-only.
and (4) beautifully and seamlessly integrates
physical and psychiatric symptomatology and
response to treatment.
So I called him up, to congratulate him and to ask if he
would be interested to see my approach of the last 11
years, which has been to include all 3 the accurate tests
in all screening and most monitoring, and to re-define the
normal range in the TSH, and possibly also in the free-T3
level. Rather than accepting that 'the tests are normal
but the patient needs treatment'. As I expected, judging
from his open-mindedness in his book, he was very
interested and we are exploring ways in which we can
collaborate in some writing in the future.
MS: What is your opinion about 'Wilson's Syndrome' and
Drs Wilson and John C Lowe's treatment with T3-only?
JD: First of all, now that we have the free-T4, free-T3 and
ultra-sensitive (3rd-generation) TSH tests, there is no
need to rely on the non-specific 'low basal body
temperature' method of diagnosis of hypothyroidism
popularized by Broda Barnes decades ago, when these new
tests were not available. If one does all 3 these
blood-tests, and reads them sensitively-enough, one can
diagnose the mildest cases of hypothyroidism accurately.
The low basal body temp. is not specific for
hypothyroidism, although common in hypothyroidism.
However, when the only test that is normally done to
screen for hypothyroidism is the TSH,
I can see where patients will become desperate enough to use any method
they can to try to establish a diagnosis of hypothyroidism when this TSH
test is "in the normal range".
Secondly, treating with T3-only is almost
as bad as treating with T4-only in most
cases and worse than T4-only in some
cases. I say 'almost as bad' because,
since 90% of thyroid function is carried
out by T3, correcting the T3 level is a
good thing. However, the brain needs T4
to be present in the blood in a good
amount because T3 doesn't cross the
'blood-brain barrier' and get into the
brain directly. T4 has to get into the
brain first and then convert to T3 in the
brain tissues. So the cognitive effects
of a low T4 level would continue because
T3-only treatment raises the T3 level a
lot, often way above normal (with all the
dangers inherent in that situation), and,
by lowering the TSH level, this also
lowers the T4 level to way-below normal. I cannot understand why anyone
would want to treat with T3-only and not use both thyroid hormones, as
needed to optimize BOTH free-levels. This is not to deny that many people
treated with T3-only will improve in many ways; after all, T3 is a very
important hormone; but they would improve much better and with less
ill-effects if both their FT4 and FT3 levels are optimized and neither one
is overtreated or undertreated.
Thirdly, my understanding is that these
people who treat with T3-only do rather
poor monitoring of thyroid blood levels
and, if they measure the T3 level at all,
it is usually the much-less-accurate
total-T3 level and not the free-T3 level,
which is the only 100%-active fraction of
the T3 in the blood. I discussed all these
issues with Dr Dennis Wilson by phone from
my then-office in Portsmouth VA in the
early 90's; I am disappointed that he
didn't see the obvious merit in my
arguments and has not modified his
approach at all. My understanding is that
John C Lowe, DC, doesn't necessarily think
that his fibromyalgia patients who respond
to T3 are necessarily hypothyroid but that
boosting the T3 level to high-normal or
even higher is somehow beneficial for such
patients. I have seen some fibromyalgia
patients respond quite dramatically to
thyroid hormone treatment, but this is not
the answer in all or even most cases. I
am also pursuing relaxin hormone and cetyl
myrist-oleate treatment in these cases,
with benefit in most of them.
(Note from Mary Shomon: For information regarding Dr. John Lowe's perspectives, see my article
Fibromyalgia Aches
and Pains as a "Symptom" of Hypothyroidism: A Look at the Theories of Dr. John Lowe, and please visit Dr. Lowe's site, at www.drlowe.com. Dr. Lowe's theories and practice are also featured in Mary Shomon's book, Living Well With Hypothyroidism. )
MS: What other deficiencies have you found often associated
with hypothyroidism that respond well to supplementation?
JD: The commonest conditions I see resulting from
hypothyroidism are: Fatigue; depression; abnormal
weight-gain; dry skin and eyes; excessive hair-loss;
memory and concentration problems; apathy; constipation;
high 'bad-cholesterol' and low 'good-cholesterol'; decline
in academic and physical/ sports performance; etc., that
are all virtually impossible to reverse without correcting
the hypothyroidism first. With optimal correction of the
hypothyroidism, these conditions will virtually all clear
up, although of course some of them may require additional
measures as well, such as depression, obesity, and dry skin.
When the necessary other measures are taken, success is
usually achieved in eliminating these
conditions.
MS: Have you found any kind of treatment program that helps
thyroid patients effectively lose weight?
JD: In addition to optimizing both the FT4 and FT3 serum
levels, I find that correcting blood-deficiencies of
chromium and manganese optimally; correcting a high
free-insulin level (Syndrome-X) with a hi-protein,
lo-carbohydrate diet; correcting many nutritional
deficiencies optimally; and encouraging plenty of
exercise, even walking, will usually achieve total or
partial excess weight loss that can be sustained
indefinitely.
References
Dommisse JV. T3 is at least as important as T4 in all cases
of hypothyroidism. J CLIN PSYCHI 1993;54,7(July):277-8.
Dommisse JV. Pseudotumor cerebri in two patients with
lithium-induced hypothyroidism. J CLIN PSYCHI
1991;52,5(May):239.
Bunevicius R, Kazanavicius G,
Zalinkevicius R, Prange AJ. Effects of thyroxine as compared
with thyroxine-plus-triiodothyronine in patients with
hypothyroidism. N ENGL J MED 1999;340:424-9.
Dommisse JV.
Hypothyroidism: Sensitive diagnosis and optimal treatment of
all types and grades. IN PRESS, 1999.
Joffe R, Blank DW,
Post RM, Uhde W. Decreased triiodothyronines (T3) in
depression: A preliminary report. BIOLOGICAL PSYCHI
1985;20:922-5.
Joffe RT, Singer W. A comparison of
triiodothyronine (T3) and thyroxine (T4) in the potentiation
of tricyclic antidepressants. PSYCHIATRIC RES 1990;32:241-51.
Palazzo MG, Suter PM. Thyroid hormone receptor expression in
'sick euthyroid' syndrome. LANCET 1990;335,Mar.17:662-3.
Cooke RG, Joffe RT, Levitt AJ. T3 augmentation of
antidepressant treatment in T4-replaced thyroid patients. J
CLIN PSYCHI 1992;53,1(Jan):16-18.
Dullaart RP, vanDoormaal JJ,
Hoogenberg K, Sluiter WJ. Triiodothyronine rapidly lowers
plasma lipoprotein(a) in hypothyroid subjects. NETH J MED 1995
Apr;46(4):179-84.
Escobar-Morreale HF, del Rey FE, Obregon MJ,
de Escobar GM. Only the combined treatment with thyroxine and
triiodothyronine ensures euthyroidism in all tissues of the
thyroidectomized rat. ENDOCRINOL 1996 Jun;137(6):2490-502.
Chopra IJ. Clinical Review 86: Euthyroid sick syndrome: Is it
a misnomer? J CLIN ENDOCRINOL METAB 1997, Feb;82(2):329-34.
DeGroot LJ. Dangerous dogmas in medicine: The nonthyroidal
illness syndrome. J CLIN ENDOCRINOL METAB 1999 Jan;
84(1):151-64.
Ferretti E, Persani L, Jaffrain-Rea ML, et al..
Evaluation of the adequacy of levothyroxine replacement
therapy in patients with central hypothyroidism. J CLIN
ENDOCRINOL METAB 1999 March;84,3:924-9.
Arem R. THE THYROID
SOLUTION: A Mind-Body Program for Beating Depression and
Regaining your Emotional and Physical Health. NewYork:
Ballantine Books, June 1999.
Finally, I'd like to salute all the hypothyroid
patients, like yourself, who have refused to
accept the half-life that results, in most
cases, from the standard treatment-approach.
'Good on you', guys!! I hope - and believe -
that you will all be richly rewarded.
John DOMmisse, MD Tucson, AZ
http://www.JohnDommisseMD.com
|